Tag: VTE

REBEL Core Cast 110.0 – On Shift Learning Pearls

Take Home Points: Patients with recent onset atrial fibrillation can safely be cardioverted if they are 1) on anticoagulation 2) Low risk based on CHADS-VASC with onset < 48 hours or 3) High risk based on CHADS-VASC with onset < …

Read More

REBEL Core Cast 85.0 – Superficial Venous Thrombosis

Take Home Points SVT >5cm or <3 cm from the SFJ should be treated with anti-coagulation.  The rate of concurrent DVT and PE in patients with SVT is 25% and 5%, respectively. 

Read More

The Pragmatic Combination of YEARS Score and Age-Adjusted D-Dimer

Background: The optimal approach to risk stratifying patients for pulmonary embolism (PE) remains elusive. Multiple decision instruments are available with varying degrees of complexity and acceptance among emergency medicine clinicians (Wells, Geneva, PERC, YEARS, age-adjusted D-dimer). The 2018 ACEP clinical …

Read More
CardiovascularHematology and OncologyThoracic and Respiratory

REBEL Cast Ep81: COVID-19, Thrombosis, and Anticoagulation

Early reports have shown that COVID-19 is most likely causing a hypercoagulable state, however the prevalence of acute VTE and exactly how to treat it is an evolving area.  Limited data suggest pulmonary microvascular thrombosis may play a role in …

Read More
Hematology and OncologyInfectious Disease

LMWH in Cancer-Related VTE (CLOT Study)

Background: Venous thromboembolism (VTE) occurs frequently in patient with cancer. Treatment in this group entails a number of challenges including a higher rate of thrombosis recurrence and a higher risk of bleeding. Standard therapy in 2018 for both symptomatic and …

Read More
Hematology and Oncology